Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events

Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events Jeffrey Weber Oncologist 2007; 12: 864-872 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in melanoma and cutaneous malignancies and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (required). Learning Objectives After completing this course, the reader should be able to: Describe the completed and ongoing clinical trials of ipilimumab in patients with advanced melanoma. Discuss the nature of immune-mediated adverse events, which are often associated with ipilimumab treatment. Describe several cases illustrating the kinetics of ipilimumab-mediated antitumor responses and the relationship to immune-mediated adverse events. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Aug. 2, 2007 Most Recent Review: Aug. 2, 2007* Most Recent Update: Aug. 2, 2007 Date Credit Expires: Aug. 2, 2009 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

• Take this course